echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Shanghai Zhenge Biotechnology Co., Ltd. raised US$100 million in Series C financing, led by Goldman Sachs and Sofina

    Shanghai Zhenge Biotechnology Co., Ltd. raised US$100 million in Series C financing, led by Goldman Sachs and Sofina

    • Last Update: 2022-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    The funds raised in the C round will be used to further strengthen Zhenge Bio’s global R&D center and expand its production capacity in compliance with Good Manufacturing Practice (GMP) to meet the needs of domestic and foreign customers


    Zhenge Bio provides one-stop contract R&D and manufacturing (CDMO) services to help customers discover, develop and manufacture biopharmaceuticals by providing end-to-end solutions from concept to commercialization


    Zhenge Bio has integrated advanced cell culture platforms, metabolite analysis platforms, recombinant protein analysis platforms and customized medium pilot production platforms for customers to help customers improve unit yield and quality


    In addition to R&D centers in Shanghai and Maryland, U.


    Zhenge Bio takes environmental, social and governance (ESG) responsibility as an integral part of its corporate strategy.


    Chen Jianxin, Chairman and CEO of Zhenge Bio, said: "We are delighted to be led by top international investment institutions such as Goldman Sachs Asset Management, Sofina and Novo Holdings in this round of financing, and thank them for their recognition and support of Zhen Ge Bio.


    Xu Xiaoou, Managing Director of Goldman Sachs Asset Management, said: "The global biopharmaceutical market is huge and developing rapidly.


    Lv Xiaotian, Head of SOFINA China, and Lin Yizhen, Investment Manager, said: "We are delighted to support Zhenge Bio


    Dr.


    About Goldman Sachs Asset Management Growth Equity 

    Goldman Sachs Asset Management integrates traditional and alternative investment businesses, serves clients globally and focuses on long-term performance


    About Sofina

    Sofina is a Brussels Stock Exchange listed, family-owned and operated investment company


    About Novo Holdings

    Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation


    Novo Holdings is recognized as a leading international life sciences investor focused on creating long-term value


    Shanghai Zhenge Biotechnology Co.



     

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.